CardioQuip, LLC – Trademark Portfolio

Entity Type: 16

CardioQuip, LLC holds 13 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 12 filings in this category. The portfolio also extends into Class 37 (Building & Construction) across 2 Nice Classification classes. Currently, 8 trademarks are registered and 2 are pending. Notable registered marks include MCH, MCH-1000, VIVACART, CARDIOCARE, and CARDIOQUIP. The owner is based in College Station, TX.

8422 Calibration Court

College Station, TX 77845

13 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CardioQuip, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (12 filings)

Surgical, medical, dental and veterinary apparatus and instruments

37
Building & Construction (1 filing)

Building construction; repair; installation services

Frequently Asked Questions

How many trademarks does CardioQuip, LLC have?

CardioQuip, LLC has 13 U.S. trademarks filed with the USPTO. Of these, 8 registered, 2 pending, 3 abandoned.

What trademark classes does CardioQuip, LLC file in?

CardioQuip, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 37 (Building & Construction). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are CardioQuip, LLC's most well-known trademarks?

CardioQuip, LLC's registered trademark portfolio includes well-known marks such as MCH, MCH-1000, VIVACART, CARDIOCARE, and CARDIOQUIP. These are among 8 currently registered trademarks in the portfolio.

What is CardioQuip, LLC's trademark registration success rate?

CardioQuip, LLC has a 73% trademark registration rate, with 8 out of 11 resolved applications resulting in successful registration. Currently, 2 applications are pending review.